Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

Table 1 Pharmacological treatments and tumor responses of DDLPD PDX models

Treatment	Route	Schedule	Dose (mg/kg)	Max TVI % (day) ^a			Tumor growth delay (days)^b
				LS-GD-1	LS-BZ-1	LS-BP-1	LS-GD-1	LS-BZ-1	LS-BP-1
Doxorubicin	i.v.	q7d×3	4	60 (49)^*	40 (17)^*	37 (46)^*	20	5	16
Selinexor	p.o.	q3/4d×8	10	80 (49)^**	55 (14)^*	46 (55)^*	> 46	7	23

^a Maximum tumor volume inhibition (TVI) % in treated versus control mice. In parentheses, the day on which it was assessed. ^*P < 0.05, ^**P < 0.005 versus control tumors
^b The tumor growth delay is calculated as the median time (days) in excess required for the tumor of the drug treated groups mice to reach 1000 mm³ compared to the diluents treated mice

ISSN: 1756-9966